ArticleNeuroImage. Clinical2020
Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up.
Article in NeuroImage. Clinical, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Scalable CT-based prognostic modeling of dementia conversion in mild cognitive impairment.Scientific reports · 2026Article
- Hippocampal volume from T1 MRI as an atrophy biomarker: automated calculation and Scheltens' scale correlation.Magma (New York, N.Y.) · 2026Article
- Longitudinal automated brain volumetry versus expert visual assessment of atrophy progression on MRI: an exploratory study.Scientific reports · 2025Article
- Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer's Disease.Nutrients · 2025Review
- The role of visual rating and automated brain volumetry in early detection and differential diagnosis of Alzheimer's disease.CNS neuroscience & therapeutics · 2024Article
- Regional MRI volumetry using NeuroQuant versus visual rating scales in patients with cognitive impairment and dementia.Brain and behavior · 2024Article
- New horizons in the diagnosis and management of Alzheimer's Disease in older adults.Age and ageing · 2024Review
- Visual atrophy rating scales and amyloid PET status in an Alzheimer's disease clinical cohort.Annals of clinical and translational neurology · 2023Review
- The role of magnetic resonance imaging in the diagnosis and prognosis of dementia.Biomolecules & biomedicine · 2023Review
- Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience.European radiology · 2022Article
- Associations of multiple visual rating scales based on structural magnetic resonance imaging with disease severity and cerebrospinal fluid biomarkers in patients with Alzheimer's disease.Frontiers in aging neuroscience · 2022Article
- Validity and reliability of the medial temporal lobe atrophy scale in a memory clinic population.BMC neurology · 2021Article
- Pre-stroke cognitive impairment is associated with vascular imaging pathology: a prospective observational study.BMC geriatrics · 2021Observational
- Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study.Journal of Alzheimer's disease : JAD · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medial temporal lobe (MTL) atrophy is an important morphological marker of many dementias and is closely related to cognitive decline. In this study we aimed to characterize longitudinal progression of MTL atrophy in 93 individuals with subjective cognitive decline and mild cognitive impairment followed up over six years, and to assess if clinical rating scales are able to detect these changes. All MRI images were visually rated according to Scheltens' scale of medial temporal atrophy (MTA) by two neuroradiologists and AVRA, a software for automated MTA ratings. The images were also segmented using FreeSurfer's longitudinal pipeline in order to compare the MTA ratings to volumes of the hippocampi and inferior lateral ventricles. We found that MTL atrophy rates increased with CSF biomarker abnormality, used to define preclinical stages of Alzheimer's Disease. Both AVRA's and the radiologists' MTA ratings showed similar longitudinal trends as the subcortical volumes, suggesting that visual rating scales provide a valid alternative to automatic segmentations. Our results further showed that it took more than 8 years on average for individuals with mild cognitive impairment, and an Alzheimer's disease biomarker profile, to increase the MTA score by one. This suggests that discrete MTA ratings are too coarse for tracking individual MTL atrophy in short time spans. While the MTA scores from each radiologist showed strong correlations to subcortical volumes, the inter-rater agreement was low. We conclude that the main limitation of quantifying MTL atrophy with visual ratings in clinics is the subjectiveness of the assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.